Market Overview

FDA Accepts NDA for Pfizer, Ligand's Bazedoxifene/Conjugated Estrogens

Related PFE
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Eli Lilly Beats on Q2 Earnings & Revs, Maintains View
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)
Related LGND
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% - Tale of the Tape
Fed Says Districts Were Optimistic On Economic Outlook; Yahoo! Falls On Downbeat Results

Pfizer Inc. (NYSE: PFE) and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis. The FDA Prescription Drug User Fee Act (PDUFA) date is October 3, 2013.

BZA/CE pairs the selective estrogen receptor modulator (SERM) bazedoxifene with conjugated estrogens. BZA/CE has been studied in a Phase III clinical development program (Selective estrogens, Menopause And Response to Therapy [SMART] trials), which included approximately 7,500 postmenopausal women and assessed the safety and efficacy of BZA/CE for the treatment of moderate-to-severe VMS and VVA associated with menopause, as well as the prevention of postmenopausal osteoporosis. The most common adverse drug reactions observed in the SMART trials were abdominal pain, vaginal yeast infection and muscle spasms.

Posted-In: News FDA

 

Most Popular

Related Articles (LGND + PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional